IN2014DN10734A - - Google Patents
Info
- Publication number
- IN2014DN10734A IN2014DN10734A IN10734DEN2014A IN2014DN10734A IN 2014DN10734 A IN2014DN10734 A IN 2014DN10734A IN 10734DEN2014 A IN10734DEN2014 A IN 10734DEN2014A IN 2014DN10734 A IN2014DN10734 A IN 2014DN10734A
- Authority
- IN
- India
- Prior art keywords
- subject
- coq1o
- coenzyme
- failed
- administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261654245P | 2012-06-01 | 2012-06-01 | |
| PCT/US2013/043785 WO2013181639A1 (en) | 2012-06-01 | 2013-05-31 | Treatment of solid tumors using coenzyme q10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN10734A true IN2014DN10734A (ja) | 2015-09-04 |
Family
ID=49673946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN10734DEN2014 IN2014DN10734A (ja) | 2012-06-01 | 2013-05-31 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US20140017317A1 (ja) |
| EP (1) | EP2854528B8 (ja) |
| JP (3) | JP6352905B2 (ja) |
| KR (2) | KR20200118233A (ja) |
| CN (1) | CN104507308A (ja) |
| AU (2) | AU2013267166A1 (ja) |
| BR (1) | BR112014029954A2 (ja) |
| CA (2) | CA2875150C (ja) |
| EA (1) | EA032345B1 (ja) |
| ES (1) | ES2761449T3 (ja) |
| HK (1) | HK1208995A1 (ja) |
| IL (1) | IL236008B (ja) |
| IN (1) | IN2014DN10734A (ja) |
| MX (2) | MX369768B (ja) |
| NZ (1) | NZ702369A (ja) |
| SG (1) | SG11201407880QA (ja) |
| WO (1) | WO2013181639A1 (ja) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA034552B1 (ru) | 2009-05-11 | 2020-02-19 | БЕРГ ЭлЭлСи | Способ лечения или предотвращения прогрессирования онкологических заболеваний |
| ES2762451T3 (es) | 2011-04-04 | 2020-05-25 | Berg Llc | Tratamiento de tumores del sistema nervioso central con coenzima Q10 |
| NZ702369A (en) * | 2012-06-01 | 2016-12-23 | Berg Llc | Treatment of solid tumors using coenzyme q10 |
| JP6731336B2 (ja) * | 2013-04-08 | 2020-07-29 | バーグ エルエルシー | コエンザイムｑ１０併用療法を用いた癌の処置方法 |
| WO2015035094A1 (en) | 2013-09-04 | 2015-03-12 | Berg Llc | Methods of treatment of cancer by continuous infusion of coenzyme q10 |
| US9996463B2 (en) * | 2015-11-10 | 2018-06-12 | International Business Machines Corporation | Selection and placement of volumes in a storage system using stripes |
| US20170189350A1 (en) * | 2015-11-16 | 2017-07-06 | Berg Llc | Methods of treatment of temozolomide-resistant glioma using coenzyme q10 |
| US20170255565A1 (en) * | 2016-03-02 | 2017-09-07 | Intel Corporation | Method and apparatus for providing a contiguously addressable memory region by remapping an address space |
| WO2018005412A1 (en) * | 2016-06-28 | 2018-01-04 | Tien Yang Der | Chemoprotective/chemoactive nanodroplets and methods of use thereof |
| EP3634391A4 (en) * | 2017-05-17 | 2021-02-24 | Berg LLC | USE OF COENZYME Q10 FORMULATIONS IN THE TREATMENT AND PREVENTION OF BUBBLE EPIDERMOLYSIS |
| AU2022400186A1 (en) * | 2021-12-01 | 2024-06-20 | Gambro Lundia Ab | New dialysis fluid |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| US20070104688A1 (en) | 2003-02-13 | 2007-05-10 | City Of Hope | Small interfering RNA mediated transcriptional gene silencing in mammalian cells |
| US8932649B2 (en) * | 2003-11-14 | 2015-01-13 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treating a neoplastic disease in a subject using inorganic selenium-containing compounds |
| ME01881B (me) * | 2004-01-22 | 2014-12-20 | Univ Miami | Topijske formulacije koenzima q10 i postupci upotrebe |
| EP2123266B1 (en) * | 2006-12-06 | 2014-01-15 | Kaneka Corporation | Cancer therapeutic agent and anti-carcinogenic agent |
| EP2136787B1 (en) | 2007-03-22 | 2019-08-21 | Berg LLC | Topical formulations having enhanced bioavailability |
| US7732491B2 (en) * | 2007-11-12 | 2010-06-08 | Bipar Sciences, Inc. | Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents |
| CA3043911A1 (en) | 2007-12-04 | 2009-07-02 | Arbutus Biopharma Corporation | Targeting lipids |
| US8247435B2 (en) * | 2009-02-19 | 2012-08-21 | Thornthwaite Jerry T | Formulations for treating human and animal diseases |
| EA034552B1 (ru) * | 2009-05-11 | 2020-02-19 | БЕРГ ЭлЭлСи | Способ лечения или предотвращения прогрессирования онкологических заболеваний |
| GB0913193D0 (en) | 2009-07-29 | 2009-09-02 | Johnson Matthey Plc | Deoxygenation process |
| PE20130045A1 (es) * | 2010-03-12 | 2013-01-28 | Berg Pharma Llc | FORMULACIONES INTRAVENOSAS DE COENZIMA Q10 (CoQ10) Y METODOS DE USO DE LAS MISMAS |
| KR102058256B1 (ko) | 2011-06-17 | 2020-01-22 | 버그 엘엘씨 | 흡입성 약제학적 조성물들 |
| NZ702369A (en) * | 2012-06-01 | 2016-12-23 | Berg Llc | Treatment of solid tumors using coenzyme q10 |
-
2013
- 2013-05-31 NZ NZ702369A patent/NZ702369A/en not_active IP Right Cessation
- 2013-05-31 BR BR112014029954A patent/BR112014029954A2/pt not_active IP Right Cessation
- 2013-05-31 CN CN201380040105.3A patent/CN104507308A/zh active Pending
- 2013-05-31 EA EA201492187A patent/EA032345B1/ru not_active IP Right Cessation
- 2013-05-31 IN IN10734DEN2014 patent/IN2014DN10734A/en unknown
- 2013-05-31 ES ES13797642T patent/ES2761449T3/es active Active
- 2013-05-31 JP JP2015515272A patent/JP6352905B2/ja active Active
- 2013-05-31 WO PCT/US2013/043785 patent/WO2013181639A1/en active Application Filing
- 2013-05-31 KR KR1020207028370A patent/KR20200118233A/ko not_active Application Discontinuation
- 2013-05-31 MX MX2014014492A patent/MX369768B/es active IP Right Grant
- 2013-05-31 EP EP13797642.9A patent/EP2854528B8/en active Active
- 2013-05-31 US US13/907,726 patent/US20140017317A1/en not_active Abandoned
- 2013-05-31 CA CA2875150A patent/CA2875150C/en active Active
- 2013-05-31 SG SG11201407880QA patent/SG11201407880QA/en unknown
- 2013-05-31 KR KR1020147037100A patent/KR102163948B1/ko active IP Right Grant
- 2013-05-31 CA CA3090268A patent/CA3090268A1/en not_active Abandoned
- 2013-05-31 AU AU2013267166A patent/AU2013267166A1/en not_active Abandoned
-
2014
- 2014-11-27 MX MX2019013776A patent/MX2019013776A/es unknown
- 2014-11-30 IL IL236008A patent/IL236008B/en active IP Right Grant
-
2015
- 2015-10-05 HK HK15109710.3A patent/HK1208995A1/xx unknown
-
2016
- 2016-10-10 US US15/289,770 patent/US20170216223A1/en not_active Abandoned
-
2017
- 2017-04-19 AU AU2017202567A patent/AU2017202567B2/en not_active Ceased
-
2018
- 2018-06-07 JP JP2018109093A patent/JP2018168164A/ja not_active Withdrawn
-
2020
- 2020-07-29 JP JP2020127877A patent/JP7225167B2/ja active Active
-
2021
- 2021-05-17 US US17/321,699 patent/US20220096399A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN10734A (ja) | ||
| IL246544A0 (en) | A compound for the treatment of patients with ros1 mutant cancer cells | |
| MX2019014986A (es) | Formulaciones de coenzima q10 y metodos de uso. | |
| EP3046622A4 (en) | Positron emission tomography guided proton therapy | |
| MX338015B (es) | Composiciones que comprenden un componente de estabilidad de la vida util. | |
| IL223889B (en) | Contrasting side effects associated with the administration of an anti-hyaluronan factor and methods for alleviating or preventing the side effects | |
| IL243927A0 (en) | A digestive enzyme preparation suitable for administration to the intestine | |
| EP3132033A4 (en) | Beta-lactamases with improved properties for therapy | |
| AU2012240222A8 (en) | Methods of treating central nervous system tumors | |
| EP3415159A4 (en) | PRE-TREATMENT MEDICAMENT FOR T-CELL PERFUSION THERAPY FOR TUMOR RESISTANT TO IMMUNE CONTROL POINT INHIBITORS | |
| EP3256133A4 (en) | Intravenous infusion dosage form | |
| EP3135293A4 (en) | Agent for preventing or ameliorating diabetes | |
| EP2982752A4 (en) | Glucuronyl transferase, gene encoding same, and use thereof | |
| MX2023003000A (es) | Formulaciones de liberacion modificada de viloxacina. | |
| GB2573925B (en) | Connection arrangements, pivots and mechanisms | |
| GEP201706636B (en) | Galactagogue compositions based on phosphatidylserine | |
| EP3318320A4 (en) | GROUP OF GRAPHITES, CARBON PARTICLES CONTAINING SAID GROUP OF GRAPHITES | |
| EP3041492A4 (en) | INHIBITING INTERACTION BETWEEN HIF-1alfa AND P300/CBP WITH HYDROGEN BOND SURROGATE-BASED HELICES | |
| EP2836217A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SIDE EFFECTS ASSOCIATED WITH THE ADMINISTRATION OF ANTICANCER CHEMOTHERAPEUTIC AGENTS | |
| ZA201802926B (en) | Electrocatalyst for the reduction of oxygen | |
| UA74355U (ru) | Способ профилактики послеродового кровотечения у женщин с привычным невынашиванием беременности в анамнезе | |
| AU340267S (en) | Kick scooters - stunt peg | |
| UA80618U (en) | Use of n-steroylethanolamine as radiomodifier | |
| UA80812U (en) | ETHYL 6-THIOXO-3-(2-FURYLMETHYL)-7-CYANO-1,3,4,6-2H-PYRIDO[1,2-a][1,3,5]TRIAZINE -9-CARBOXYLATE | |
| UA84204U (ru) | Способ иммунокоррекции больных ветряной оспой с наличием иммунодефицитных состояний |